InspireMD wins FDA nod for CGuard Prime TCAR stent, Q3 loss $0.12/share.
Sentimentbullish 80
Strongly bullish · 80 of 100
Impact80
high · market-wide
Confidence90%
high confidence · 4 wires
Eventdeveloping
v4 · alerted to followers
FREE ACCOUNT · NO CARD
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
WHY IT MATTERS••••••••••Market transmission and exposed assetsBULL / BEAR CASE•••• / ••••Competing evidence, edited togetherNEWS ON PRICE••.•% reactionConfirmation versus SPY and sectorWHAT TO WATCH•• catalystsThe facts that can change the read
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
InspireMD gets FDA approval for CGuard Prime stent in TCAR proceduresbullish 80 · impact 70
InspireMD reports Q3 loss, highlights FDA approval for CGuard Prime TCAR stentneutral 50 · impact 30
InspireMD reports Q3 loss of 12 cents per sharebearish 40 · impact 20 · this page
InspireMD gets FDA approval for CGuard Prime stent in TCAR proceduresbullish 85 · impact 80 · first wire
Where this story sitsringed dot is this story
bullishneutralbearishlabel = ticker sentiment·impact · dot size follows impact · click a dot to open the story
Every story, completefree account
A free account opens the reasons behind every story, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone, plus 3 complete ticker and report views a day. BORSA Plus removes the daily limit and adds alerts on your names.
BORSA uses AI-assisted classification and synthesis with deterministic event controls. Market sentiment is informational and is not individualized investment advice.
